Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 12 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
PharmaSci from Rotselaar, company number BE0636973759, closed financial year 2025 with a result of € 61,401 after tax. For that financial year PharmaSci recorded a gross margin of € 94,096 and equity of € 843,807. Compared with financial year 2024, the result moved from € 116,038 to € 61,401. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 21, 2026.
€ 843,807
▲ 8% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 61,401
▼ 47% vs 2024
Profit after tax over the fiscal year.
€ 146
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 825,207.
Debts at end 2025
€ 556,007
▼ 16% vs 2024
€ 90,539 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.
€ 996
▼ 80% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 58,008
▲ 48% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 141,849 | € 164,639 | € 173,598 | € 94,096 | ▼ 46% |
| Profit after taxes | € 93,732 | € 112,067 | € 116,038 | € 61,401 | ▼ 47% |
| Equity | € 541,901 | € 666,368 | € 782,406 | € 843,807 | ▲ 8% |
| Total debts | € 1,129,168 | € 1,012,680 | € 896,316 | € 858,781 | ▼ 4% |
| Cash | € 6,099 | € 8,410 | € 0 | € 146 | |
| Retained profit | € 535,701 | € 647,768 | € 763,806 | € 825,207 | ▲ 8% |
| Bank debt | € 881,347 | € 786,244 | € 665,782 | € 556,007 | ▼ 16% |
| Balance sheet total | € 1,671,069 | € 1,679,048 | € 1,678,722 | € 1,702,588 | ▲ 1% |
Key figures of PharmaSci, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PharmaSci?
What happened at PharmaSci in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 61,401 (▼ 47% vs 2024). filed late Source: NBB ↗
- New establishment in Rotselaar. KBO
- Start of the company according to the CBE. KBO
In short
From € 93,732 profit in 2022 to € 61,401 profit in 2025.
Paid € 119,103 in corporate taxes since 2022.
Best year ever: 2024, with € 116,038 profit.
Management
Behind PharmaSci is Kristien Daenen. It owns 100% of Apotheek Daenen itself.
Directors
According to the 2025 annual accounts
Establishments
Establishment units
Physical locations of this company
Stationsstraat 19
3110 Rotselaar
Steenweg op Gelrode 46
3110 Rotselaar
Active since 11 September 2015
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0636.973.759
- VAT number
- BE 0636.973.759
- Registered office
- Stationsstraat 19, 3110 Rotselaar
- Names & denominations
- PharmaSci
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 11 September 2015
- Peppol
- Active · Active since 18 Nov 2025
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Activiteiten op het gebied van voeding
Overige menselijke gezondheidszorg, n.e.g.